Literature DB >> 29935846

GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma.

Liang Zeng1, Nong Yang1, Yongchang Zhang2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29935846     DOI： 10.1016/j.jtho.2018.02.005

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  19 in total

Review 1.  Overcoming therapy resistance in EGFR-mutant lung cancer.

Authors:  Pasi A Jänne; Tony Mok; Solange Peters; Antonio Passaro
Journal:  Nat Cancer       Date:  2021-04-15

Review 2.  Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Authors:  Alissa J Cooper; Lecia V Sequist; Jessica J Lin
Journal:  Nat Rev Clin Oncol       Date:  2022-05-09       Impact factor: 65.011

Review 3.  Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?

Authors:  Elisa Bertoli; Elisa De Carlo; Alessandro Del Conte; Brigida Stanzione; Alberto Revelant; Kelly Fassetta; Michele Spina; Alessandra Bearz
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

4.  Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.

Authors:  Jiao-Li Wang; Liu-Sheng Wang; Jun-Qi Zhu; Jie Ren; Di Wang; Man Luo
Journal:  Respirol Case Rep       Date:  2022-10-17

Review 5.  Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.

Authors:  Catherine B Meador; Aaron N Hata
Journal:  Pharmacol Ther       Date:  2020-03-06       Impact factor: 12.310

6.  Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution.

Authors:  Dan Li; Li Ding; Wenwen Ran; Yan Huang; Guangqi Li; Chengqin Wang; Yujing Xiao; Xiaonan Wang; Dongliang Lin; Xiaoming Xing
Journal:  Thorac Cancer       Date:  2020-07-30       Impact factor: 3.500

Review 7.  PDZ Domains as Drug Targets.

Authors:  Nikolaj R Christensen; Jelena Čalyševa; Eduardo F A Fernandes; Susanne Lüchow; Louise S Clemmensen; Linda M Haugaard-Kedström; Kristian Strømgaard
Journal:  Adv Ther (Weinh)       Date:  2019-04-24

8.  Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia.

Authors:  Nahla A Mobark; Musa Alharbi; Lamees Alhabeeb; Latifa AlMubarak; Rasha Alaljelaify; Mariam AlSaeed; Amal Almutairi; Fatmah Alqubaishi; Maqsood Ahmad; Ayman Al-Banyan; Fahad E Alotabi; Duna Barakeh; Malak AlZahrani; Hisham Al-Khalidi; Abdulrazag Ajlan; Lori A Ramkissoon; Shakti H Ramkissoon; Malak Abedalthagafi
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240

Review 9.  Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer.

Authors:  Beatrice Gini; Nicholas Thomas; Collin M Blakely
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

Review 10.  Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Authors:  Alessandro Leonetti; Sugandhi Sharma; Roberta Minari; Paola Perego; Elisa Giovannetti; Marcello Tiseo
Journal:  Br J Cancer       Date:  2019-09-30       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.